A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Public ClinicalTrials.gov record NCT01846416. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows: 1. Participants with no prior chemotherapy for advanced disease; 2. Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); 3. Participants who are 2L+ and previously treated for brain metastases.
Study identification
- NCT ID
- NCT01846416
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2013 (Actual)
- Primary completion
- Jan 7, 2015 (Actual)
- Completion
- Dec 18, 2017 (Actual)
- Last update posted
- Jan 8, 2019
2013 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute - Pima Center | Scottsdale | Arizona | 85258 | — |
| Stanford University/Lucile Packard Children's Hospital | Palo Alto | California | 94304 | — |
| The Angeles Clinic and Research Institute, Santa Monica Office | Santa Monica | California | 90025 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06510 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Florida Hospital Cancer Inst | Orlando | Florida | 32804 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Florida Cancer Specialists. | St. Petersburg | Florida | 33705 | — |
| H. Lee Moffitt Cancer Center and Research Inst. | Tampa | Florida | 33612 | — |
| Northwest Georgia Oncology Centers P.C. | Carrollton | Georgia | 30117 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Dartmouth Hitchcock Med Center; Norris Cotton Cancer Ctr | Lebanon | New Hampshire | 03756 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Health Systems | Durham | North Carolina | 27710 | — |
| Carolina BioOncology Institute; Can Therapy & Res Ctr | Huntersville | North Carolina | 28078 | — |
| Ohio State Uni Hospital | Columbus | Ohio | 43210-1250 | — |
| Oncology Hematology Care, Inc. | Hamilton | Ohio | 45103 | — |
| Penn State Univ. Milton S. Hershey Medical Center; MSHMC Cardiology | Hershey | Pennsylvania | 17033 | — |
| Penn Presbyterian Medical Center; Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| SCRI-Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Huntsman Cancer Institute; University of Utah | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
| University of Washington Seattle Cancer Care Alliance | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01846416, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2019 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01846416 live on ClinicalTrials.gov.